

AMOEBBA extends the protection of its technology in France and China

Lyon (France), January 18th, 2017 - AMOEBBA (FR0011051598 - AMEBBA), producer of a biological biocide capable of eliminating bacterial risk in water, announced today that it has been granted three new patents, two in China and one in France, extending the protection of its technology on a new territory and a new application for its biological biocide.

Two patents have been granted in China by the Chinese Intellectual Property Office including:

- The patent “Method for the biological control of *Listeria*”, pathogenic bacteria leading to food-borne disease, and
- The patent “Method for the biological control of *Pseudomonas*, primary germ responsible for nosocomial infections in healthcare institutions.

Those patents are the first granted in China for the three patent families held by AMOEBBA.

The company has been granted a third patent « Method for the biological control of *Naegleria fowleri* », in France, by the Industrial Property National Institute. This patent is the first one granted for this family. It confirms the action of the active substance BIOMEBA, *Willaertia magna C2c Maky*, against the *Naegleria fowleri* amoeba which is responsible for the primitive amoebic meningoencephalitis, severe disease leading very often to deaths (95% of the cases). The control of this germ is of particular interest to the French nuclear plant market insofar its monitoring is required from a regulatory standpoint.

*« The two patents granted in China allow us to develop our influence on a territory with a strong commercial potential and to look for new partnership in China based on our know-how and our patent portfolio.» stated **Fabrice PLASSON, President of the Board of AMOEBBA.** “*Naegleria fowleri* is mainly present in hot water such as cooling water in nuclear plants – a market estimated at 1.7 billion euros and targeted by AMOEBBA in the near future. » added **Fabrice PLASSON.***



About AMOEBA:

AMOEBBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector and complies with the new regulations in terms of chemical emissions into the environment. In a worldwide market for chemical biocides estimated to be worth EUR 21 bn⁽¹⁾, AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT), estimated to be worth EUR 1.7 bn⁽²⁾. AMOEBA is continuing with the regulatory procedures necessary to obtain provisional MA for all European countries for the “Air Cooled Towers” application. Based in Lyon-Chassieu (France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. For more information: www.amoeba-biocide.com.

(1): Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(2): Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

Contacts:

Amoéba
Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Financial Communication
Tel. : +33 (0)1 56 88 11 11
[ggasparetto@actifin.fr](mailto:gasparetto@actifin.fr)